Massive SMA study reveals Real-World treatment patterns
NCT ID NCT07403214
First seen Feb 24, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study looked at medical records of over 4,800 people with spinal muscular atrophy (SMA) to see how three approved treatments (onasemnogene abeparvovec, nusinersen, and risdiplam) are used in real life. Researchers tracked complications, medical equipment needs, and hospital visits before and after starting these treatments. The goal was to understand treatment patterns and outcomes outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.